Abstract | BACKGROUND: PATIENTS AND METHODS: RESULTS: 25(OH)D-3 increased (p<0.01) only in the groups receiving 2,000 IU vitamin D-3. PGE2 decreased in the breast (p=0.01) only after receiving 2,000 IU vitamin D-3; 2,000 IU vitamin D-3 alone was more effective in decreasing PGE2 than 2,000 IU vitamin D-3 plus celecoxib (p=0.018). COX2 expression decreased only in the breasts of women taking 2,000 IU vitamin D-3. Change in circulating 25(OH)D-3 correlated with change in TGFβ2 in the breast. CONCLUSION:
Vitamin D-3 reduces the PG cascade and increases TGFβ2 in a dose-dependent fashion. Adding celecoxib did not provide synergy.
|
Authors | Wenyi Qin, Claris Smith, Mark Jensen, Michael F Holick, Edward R Sauter |
Journal | Anticancer research
(Anticancer Res)
Vol. 33
Issue 9
Pg. 3861-6
(Sep 2013)
ISSN: 1791-7530 [Electronic] Greece |
PMID | 24023320
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Placebos
- Prostaglandin Antagonists
- Pyrazoles
- Sulfonamides
- Transforming Growth Factor beta
- Vitamin D
- Cholecalciferol
- RNA
- 25-hydroxyvitamin D
- Cyclooxygenase 2
- Celecoxib
- Dinoprostone
|
Topics |
- Adult
- Celecoxib
- Cholecalciferol
(pharmacology)
- Cyclooxygenase 2
(genetics)
- Dinoprostone
(blood, metabolism)
- Double-Blind Method
- Female
- Humans
- Middle Aged
- Neoplasms
(metabolism)
- Placebos
- Prostaglandin Antagonists
(pharmacology)
- Pyrazoles
(pharmacology)
- RNA
(blood)
- Reference Values
- Sulfonamides
(pharmacology)
- Transforming Growth Factor beta
(blood)
- Vitamin D
(analogs & derivatives, blood)
|